尿路上皮癌抗体偶联药物靶点研究进展：NECTIN⁃4、HER⁃2与TROP⁃2的临床价值与未来挑战

doi:10.3969/j.issn.1674-5671.2025.06.04

Abstract

Abstract: Antibody⁃drug conjugate (ADC) have revolutionized the treatment paradigm for advanced urothelial carcinoma (UC) through their dual mechanism of precise targeting and effective cytotoxicity. This article examines the expression profiles of NECTIN⁃4, HER⁃2 and TROP⁃2 in UC and their biological basis as ADC targets. By integrating key clinical trial data from recent years, it thoroughly explores the breakthrough advances of ADCs therapy of locally advanced/metastatic UC, the challenges related to biomarkers, and future development directions. This study provides new insights for the precise diagnosis and treatment of UC and provides evidence⁃based support for clinical practice.

Key words: Urothelial carcinoma, Antibody?drugconjugate, Targeted therapy, Combination therapy

CLC Number:

R737.15

ZHANG Wentao, LIU Yongqiang, WU Yang, CHEN Haotian, GUO Yadong, ZHANG Junfeng, MAO Shiyu, SHEN Liliang, MA Wenchao, WANG Ruiliang, XU Tianyuan, GENG Jiang, SHEN . Research progress on targets for antibody⁃drug conjugate in urothelial carcinoma: clinical value and future challenges of NECTIN⁃4,HER⁃2,and TROP⁃2[J].Chinese Journal of Oncology Prevention and Treatment, 2025, 17(6): 672-682.

[1]	LIU Meng, LIAO Dezhong, MA Hong. Research advances in alternative splicing in tumor metabolic reprogramming and targeted therapy [J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(4): 490-495.
[2]	ZHU Junming, DENG Hongbin, CAO Xinyi. Research advances in the application of stereotactic body radiation therapy for oligometastatic and oligoprogressive renal cell carcinoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(2): 250-256.
[3]	ZHONG Limei, JIN Feng. Advance in treatment of recurrent/metastatic nasopharyngeal carcinoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(2): 215-222.
[4]	NIU Xia, ZHANG Xiaojuan, BI Yanghui, ZHANG Ling. Effect of proteasome inhibitor bortezomib on the growth of esophageal squamous cell carcinoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(6): 461-466.
[5]	PANG Sen, WU Xianghua, LI Guibin, CHEN Jun, HUANG Jingle. Effect of silencing ERK5 on the biological function of gastric cancer SGC-7901 and BGC-823 cells [J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(3): 233-238.
[6]	Qin Zhijun,Huang Lu,Zeng Xiaoyi,Yang Weiping,Liao Xiaoli,Li Yongqiang,Wei Changyuan,Liu Zhihui. Expression of FPN1 and DMT1 in hepatocellular carcinoma tissues and relationship with efficacy of chemotherapy or sorafenib [J]. Chinese Journal of Oncology Prevention and Treatment, 2017, 9(5): 373-378.
[7]	WU Jin-tong,PENG Jun-ying,WU Chen-bing,SHEN Fen. Clinical observation of locally advanced nasopharyngeal carcinoma treated by three-dimensional conformal radiation therapy（3DCRT）/intensity-modulated radiation therapy （IMRT） and synchronous cisplatin chemotherapy combined with Nimotuzumab [J]. Chinese Journal of Oncology Prevention and Treatment, 2014, 6(1): 47-51.
[8]	WEI Jin-song,LI Zhi-ge,SONG Xiang-qun,et al.. Preliminary observation of Herceptin-combined chemotherapy on Her-2 over-expressing metastatic breast cancer [J]. Chinese Journal of Oncology Prevention and Treatment, 2010, 2(01): 22-24.

Research progress on targets for antibody⁃drug conjugate in urothelial carcinoma: clinical value and future challenges of NECTIN⁃4,HER⁃2,and TROP⁃2

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Metrics

Comments

Recommended 0